Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease

This 2008 Inflammatory Bowel Diseases paper from the Brzoska–Luger and Kucharzik groups in Münster is the companion mouse-model paper to Dalmasso 2008 — co-published in the same calendar quarter, drawing on complementary experimental designs, and together forming the mechanistic foundation for KPV as an inflammatory-bowel-disease candidate. The authors tested orally administered KPV in two independent murine colitis models: dextran-sodium-sulfate (DSS) acute colitis and CD45RBhi T-cell-transfer chronic colitis. KPV-treated animals in the DSS model showed earlier weight recovery, significantly reduced inflammatory cell infiltrates on histology, and reduced colon myeloperoxidase activity — the same pattern of findings the Merlin group reported in the parallel Gastroenterology paper. Crucially, the authors then repeated the DSS experiment in MC1Re/e mice (carrying a non-functional melanocortin-1 receptor): KPV still attenuated colitis severity and rescued every animal in the treatment group from disease-induced mortality, confirming that the anti-inflammatory effect operates independently of MC1R signalling. The CD45RBhi transfer model — a T-cell-driven chronic colitis with stronger relevance to human Crohn's-disease biology — also responded to KPV with reduced histological severity and lower colonic pro-inflammatory cytokine expression. Together with Dalmasso 2008, this paper established that KPV's activity in IBD models is real, reproducible across mechanistic frameworks, and dissociated from the pigmentary side of melanocortin biology.